Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Imke Satzger"'
Autor:
Katharina C. Kähler, Ralf Gutzmer, Friedegrund Meier, Lisa Zimmer, Markus Heppt, Anja Gesierich, Kai-Martin Thoms, Jochen Utikal, Jessica C. Hassel, Carmen Loquai, Claudia Pföhler, Lucie Heinzerling, Martin Kaatz, Daniela Göppner, Annette Pflugfelder, Ann-Sophie Bohne, Imke Satzger, Lydia Reinhardt, Jan-Malte Placke, Dirk Schadendorf, Selma Ugurel
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the associ
Externí odkaz:
https://doaj.org/article/a2a4359c2b56408ebeb8ee6646dc44b5
Autor:
Nikolai Gräger, Mareike Leffler, Jens Gottlieb, Jan Fuge, Gregor Warnecke, Ralf Gutzmer, Imke Satzger
Publikováno v:
Journal of Skin Cancer, Vol 2019 (2019)
Background. Nonmelanoma skin cancer (NSMC) is the most common malignancy after organ transplantation. Lung transplant recipients (LTRs) are particularly prone to develop NMSC as compared to renal or hepatic transplant recipients due to higher dosages
Externí odkaz:
https://doaj.org/article/a14589c851aa4a3e8f0c7a4948b4d3c0
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 18:1495-1497
Autor:
Kurt-Wolfram Sühs, Nora Möhn, Martin Stangel, Ralf Gutzmer, Imke Satzger, Thomas Skripuletz, Stefan Gingele, Yenny Angela
Publikováno v:
Melanoma Research. 29:435-440
Targeting immune cells instead of cancer cells is a new and successful therapeutic approach in patients with a variety of advanced cancers. Blocking antibodies bind to specific immune-checkpoint molecules namely cytotoxic T-lymphocyte-associated anti
Autor:
Carsten Weishaupt, Vesna Alar, Sebastian Haferkamp, Ralf Gutzmer, Jürgen C. Becker, Imke Satzger, Selma Ugurel, Yenny Angela, Florian Oberndörfer
Publikováno v:
Cancer Immunology, Immunotherapy. 68:1187-1194
PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for the prevention of skeletal-related events.
Autor:
Martin Stangel, Thomas Skripuletz, Susann Mahjoub, Imke Satzger, Gernot Beutel, Nora Möhn, Mike P. Wattjes, Heiko Golpon, Ralf Gutzmer, Philipp Ivanyi
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2020 (2020)
Journal of Oncology, Vol 2020 (2020)
Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced me
Autor:
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53745 (2013)
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimum
Externí odkaz:
https://doaj.org/article/1e9dff99dd604582ac2c2c7a3f9fad75
Publikováno v:
Journal of Dermatological Science. 92:172-180
Background Due to their immunosuppressive therapy, organtransplant recipients (OTRs) exhibit a high incidence for the development of cutaneous squamous cell carcinoma (cSCC). Randomized studies of kidney-transplanted patients indicate a significant l
Autor:
Florian Länger, Imke Satzger, Markus Cornberg, Hans-Heinrich Kreipe, Gernot Beutel, Philipp Ivanyi, Ralf Gutzmer, Katrin Schaper-Gerhardt
Publikováno v:
European Journal of Cancer. 93:150-153
Autor:
Michael Max Sachse, Hanna Blasig, Carolin Bender, Thomas Eigentler, Julia Hiernickel, Jessica C. Hassel, Imke Satzger, Anika Koop, Ralf Gutzmer
Publikováno v:
Melanoma Research. 27:321-325
Significant progress has been made in the treatment of metastatic melanoma during the last years. Approval of immune-checkpoint inhibitors and targeted therapies has been achieved recently. The sequencing of these therapies is an important issue. Her